SRC and breast cancer: The co-administration of Src/FAK inhibitors and GnRH receptor antagonists (degarelix) counteracted BC growth and metastasis and augmented animal survival, whereas the use of leuprorelin (a GnRH receptor agonist) favored tumor progression and controlled gene expression associated with tumor progression [95].